A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score

被引:102
|
作者
Quast, Anne-Floor B. E. [1 ]
Baalman, Sarah W. E. [1 ]
Brouwer, Tom F. [1 ]
Smeding, Lonneke [1 ]
Wilde, Arthur A. M. [1 ]
Burke, Martin C. [1 ,2 ]
Knops, Reinoud E. [1 ]
机构
[1] Univ Amsterdam, Amsterdam UMC, Dept Clin & Expt Cardiol, Ctr Heart, POB 22700,Meibergdreef 9, Amsterdam, Netherlands
[2] CorVita Sci Fdn, Chicago, IL USA
关键词
Conversion testing; Defibrillation testing; Implantation; Subcutaneous implantable cardioverter-defibrillator; SHOCK IMPEDANCE; THRESHOLD; EFFICACY; OUTCOMES; SAFETY;
D O I
10.1016/j.hrthm.2018.09.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Suboptimal positioning of the subcutaneous implantable cardioverter-defibrillator (S-ICD) increases the defibrillation threshold and risk of conversion failure. OBJECTIVE Our objective is to develop a tool to evaluate the implant position and predict defibrillation success of the S-ICD: the PRAETORIAN score. METHODS The PRAETORIAN score is based on clinical and computer modeling knowledge of determinants affecting the defibrillation threshold: subcoil fat, subgenerator fat, and anterior positioning of the S-ICD generator. The score evaluates these determinants on the postoperative anterior-posterior and lateral chest radiographs and has 3 categories: 30-<90 points representing a low risk, 90-<150 points representing an intermediate risk, and >= 150 points representing a high risk of conversion failure. The score was developed using 2 separate S-ICD data sets for derivation and validation. The performance metrics are the positive and negative predictive values. RESULTS The development data set consisted of 181 patients with S-ICD, and the validation cohort consisted of 321 patients from the S-ICD Investigational Device Exemption trial. The distribution of scores was 93%-98% low risk (<90 points), 2%-5% intermediate risk (90-<150 points), and 1% high risk (>= 150 points). The positive predictive value for an intermediate or high PRAETORIAN score for a failed conversion test was 51%, while a low PRAETORIAN score predicted a successful conversion in 99.8% of patients. CONCLUSION The PRAETORIAN score allows the identification of patients with high defibrillation thresholds by using the routine chest radiograph and provides feedback to implanters on S-ICD positioning. The PRAETORIAN-DFT trial will prospectively validate the score by randomizing to standard conversion testing vs using the score without conversion testing.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 26 条
  • [1] Validation of the PRAETORIAN score in a large subcutaneous implantable cardioverter-defibrillator collective: Usefulness in clinical routine
    Doldi, Florian
    Frommeyer, Gerrit
    Loeuroher, Andreas
    Ellermann, Christian
    Wolfes, Julian
    Gueuroner, Fatih
    Zerbst, Mathis
    Engelke, Hauke
    Korthals, Dennis
    Reinke, Florian
    Eckardt, Lars
    Willy, Kevin
    HEART RHYTHM, 2024, 21 (07) : 1057 - 1063
  • [2] Minimal defibrillation thresholds and the correlation with implant position in subcutaneous implantable-defibrillator patients
    Quast, Anne-Floor B. E.
    Baalman, Sarah W. E.
    Van der Stuijt, Willeke
    Wilde, Arthur A. M.
    Knops, Reinoud E.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2019, 30 (11) : 2441 - 2447
  • [3] Defibrillation testing of the subcutaneous implantable cardioverter-defibrillator at the time of generator replacement
    Schaller, Robert D.
    Hyman, Matthew
    Supple, Gregory E.
    Santangeli, Pasquale
    Riley, Michael P.
    Nazarian, Saman
    Arkles, Jeffrey
    Garcia, Fermin
    Lin, David
    Guandalini, Gustavo
    Kumareswaran, Ramanan
    Deo, Rajat
    Bode, Weeranun
    Markman, Timothy
    Epstein, Andrew
    Callans, David J.
    Dixit, Sanjay
    Brozoski, Joseph
    Marchlinski, Francis E.
    Frankel, David S.
    HEART RHYTHM, 2024, 21 (01) : 117 - 118
  • [4] Defibrillation testing during implantation of the subcutaneous implantable cardioverter-defibrillator: a necessary standard or becoming redundant?
    van der Stuijt, W.
    Quast, A. B. E.
    Knops, R. E.
    NETHERLANDS HEART JOURNAL, 2020, 28 (SUPPL 1) : 122 - 127
  • [5] The risk of failure of subcutaneous implantable cardioverter defibrillator therapy: from PRAETORIAN score to clinical practice
    Ziacchi, Matteo
    Ottaviano, Luca
    Checchi, Luca
    Viani, Stefano
    Nigro, Gerardo
    Bianchi, Valter
    De Bonis, Silvana
    De Filippo, Paolo
    Francia, Pietro
    Rapacciuolo, Antonio
    Vitulano, Gennaro
    Perego, Giovanni Battista
    Schillaci, Vincenzo
    Lavalle, Carlo
    Migliore, Federico
    Pisano, Ennio C. L.
    Compagnucci, Paolo
    Palmisano, Pietro
    Botto, Gianluca
    Rordorf, Roberto
    Lovecchio, Mariolina
    Valsecchi, Sergio
    Biffi, Mauro
    S ICD Rhythm Detect Investigators
    EUROPACE, 2025, 27 (02):
  • [6] Subcutaneous implantable cardioverter-defibrillator and defibrillation testing: A propensity-matched pilot study
    Forleo, Giovanni B.
    Gasperetti, Alessio
    Breitenstein, Alexander
    Laredo, Mikael
    Schiavone, Marco
    Ziacchi, Matteo
    Vogler, Julia
    Ricciardi, Danilo
    Palmisano, Pietro
    Piro, Agostino
    Compagnucci, Paolo
    Waintraub, Xavier
    Mitacchione, Gianfranco
    Carrassa, Gianmarco
    Russo, Giulia
    De Bonis, Silvana
    Angeletti, Andrea
    Bisignani, Antonio
    Picarelli, Francesco
    Casella, Michela
    Bressi, Edoardo
    Rovaris, Giovanni
    Calo, Leonardo
    Santini, Luca
    Pignalberi, Carlo
    Lavalle, Carlo
    Viecca, Maurizio
    Pisano, Ennio
    Olivotto, Iacopo
    Curnis, Antonio
    Dello Russo, Antonio
    Tondo, Claudio
    Love, Charles J.
    Di Biase, Luigi
    Steffel, Jan
    Tilz, Roland
    Badenco, Nicolas
    Biffi, Mauro
    HEART RHYTHM, 2021, 18 (12) : 2072 - 2079
  • [7] Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry The EFFORTLESS Study
    Boersma, Lucas
    Barr, Craig
    Knops, Reinoud
    Theuns, Dominic
    Eckardt, Lars
    Neuzil, Petr
    Scholten, Marcoen
    Hood, Margaret
    Kuschyk, Juergen
    Jones, Paul
    Duffy, Elizabeth
    Husby, Michael
    Stein, Kenneth
    Lambiase, Pier D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (07) : 830 - 841
  • [8] Defibrillation testing is mandatory in patients with subcutaneous implantable cardioverter-defibrillator to confirm appropriate ventricular fibrillation detection
    de Waroux, Jean-Benoit le Polain
    Ploux, Sylvain
    Mondoly, Pierre
    Eschalier, Romain
    Strik, Marc
    Houard, Laura
    Pierre, Bertrand
    Buliard, Samuel
    Klotz, Nicolas
    Ritter, Philippe
    Haissaguerre, Michel
    Mahfouz, Karim
    Bordachar, Pierre
    HEART RHYTHM, 2018, 15 (05) : 642 - 650
  • [9] Novel intravascular defibrillator: Defibrillation thresholds of intravascular cardioverter-defibrillator compared to conventional implantable cardioverter-defibrillator in a canine model
    Sanders, William E., Jr.
    Richey, Mark W.
    Malkin, Robert A.
    Masson, Stephen C.
    Ransbury, T. J.
    Urtz, Mark W.
    Ideker, Raymond E.
    HEART RHYTHM, 2011, 8 (02) : 288 - 292
  • [10] Evaluation of a novel automatic screening tool for determining eligibility for a subcutaneous implantable cardioverter-defibrillator
    Sakhi, Rafi
    Yap, Sing-Chien
    Michels, Michelle
    Schinkel, Arend F. L.
    Kauling, R. Martijn
    Roos-Hesselink, Jolien W.
    Theuns, Dominic A. M. J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 272 : 97 - 101